Vietnam is rapidly emerging as one of Southeast Asia's most attractive destinations for pharmaceutical contract manufacturing, as international drug manufacturers seek to diversify supply chains, expand regional production and strengthen resilience following recent global supply chain disruptions.
While no dedicated valuation for Vietnam's pharmaceutical contract manufacturing market has yet been published, industry analysis estimates the market is currently worth US$420–550 million in 2025 and is projected to reach US$750 million to US$1 billion by 2030.
The market encompasses a broad range of Contract Manufacturing Organisation (CMO) and Contract Development and Manufacturing Organisation (CDMO) services, including:
- Drug formulation and development
- Active Pharmaceutical Ingredient (API) manufacturing
- Finished dosage manufacturing
- Sterile injectables and fill-finish operations
- Biologics manufacturing
- Packaging and labelling
- Analytical testing and quality assurance
- Technology transfer and scale-up
- Regulatory support
Several structural trends are accelerating market growth across Vietnam:
- Expansion of domestic pharmaceutical manufacturing capacity.
- Government policies encouraging local production and reducing dependence on imported medicines.
- Increasing outsourcing by multinational pharmaceutical companies.
- Growing demand for generic medicines and biosimilars.
- Rising investment in biologics, vaccines and sterile manufacturing facilities.
- Expansion of EU-GMP and PIC/S-compliant manufacturing plants.
- Increasing foreign direct investment and technology transfer into Vietnam's pharmaceutical sector.
Vietnam's wider pharmaceutical industry provides a strong foundation for contract manufacturing. According to IMARC Group, the country's pharmaceutical market reached US$7.98 billion in 2025 and is forecast to grow to US$14.65 billion by 2034, driven by rising healthcare expenditure, an ageing population and increasing demand for both innovative and generic medicines.
The API sector is also expanding rapidly. Vietnam's Active Pharmaceutical Ingredients (API) market reached US$1.05 billion in 2025 and is expected to approach US$1.91 billion by 2034, reflecting increasing investment in local pharmaceutical production and reduced reliance on imported ingredients. Generic APIs currently account for the largest share of manufacturing activity, while biologic APIs represent one of the fastest-growing segments.
Biopharmaceutical manufacturing is creating further opportunities for CDMOs. IMARC Group estimates Vietnam's biopharmaceutical market reached US$1.4 billion in 2025 and is projected to double to US$2.8 billion by 2034. Growth is supported by increasing production of monoclonal antibodies, recombinant proteins, vaccines and biosimilars, creating demand for specialised development and manufacturing partners.
Momentum is also being reinforced by major investments in local manufacturing. In 2025, Sanofi and Vietnam Vaccine JSC (VNVC) launched construction of a vaccine manufacturing facility in Long An Province with an initial investment of approximately US$77 million. The facility is expected to produce up to 100 million vaccine doses annually from 2027, demonstrating growing international confidence in Vietnam as a pharmaceutical manufacturing hub.
Technological innovation is transforming pharmaceutical contract manufacturing worldwide. Modern CDMOs increasingly offer integrated services spanning formulation development, continuous manufacturing, advanced aseptic processing, biologics production, automation, digital quality management and AI-enabled manufacturing analytics. These capabilities enable pharmaceutical companies to accelerate product development while reducing capital investment and improving manufacturing flexibility.
Leading global CDMOs including Lonza, Catalent, Thermo Fisher Scientific (Patheon), Recipharm, PCI Pharma Services, Samsung Biologics, WuXi Biologics, AGC Biologics, Fujifilm Diosynth Biotechnologies and Cambrex continue to expand manufacturing capacity across Asia-Pacific as pharmaceutical outsourcing continues to grow.
As Vietnam strengthens its pharmaceutical manufacturing ecosystem and advances its ambition to become a regional life sciences hub, contract manufacturing is expected to play an increasingly important role in supporting drug development, biologics production and export growth. For suppliers of pharmaceutical processing equipment, cleanroom technologies, fill-finish systems, packaging, quality assurance solutions and manufacturing automation, Vietnam represents one of Southeast Asia's most compelling long-term investment opportunities.
